Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GIM-531 + unspecified PD-1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GIM-531 | GIM 531|GIM531 | GIM-531 is a small molecule regulatory T-cell (Treg) inhibitor, which potentially reduces Treg-mediated immunosuppression and increases antitumor immune response (NCI Drug Dictionary). | ||
| unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06425926 | Phase Ib/II | GIM-531 + unspecified PD-1 antibody GIM-531 | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Recruiting | USA | 0 |